☆ 4.5 Article

Expanding inclusion criteria for active surveillance in intermediate-risk prostate cancer: a machine learning approach

WORLD JOURNAL OF UROLOGY (2023)

Related references

Note: Only part of the references are listed.

Article Urology & Nephrology

Gleason Grade 1 Prostate Cancer Volume at Biopsy Is Associated With Upgrading but Not Adverse Pathology or Recurrence After Radical Prostatectomy: Results From a Large Institutional Cohort

Kevin Shee et al.

Summary: This study aimed to investigate the association between low-grade prostate cancer volume and outcomes in men who underwent primary radical prostatectomy. The results showed that tumor volume was associated with upgrading at radical prostatectomy, but not with adverse pathology or recurrence.

JOURNAL OF UROLOGY (2023)

Add to Collection

Review Urology & Nephrology

Systematic Review of Active Surveillance for Clinically Localised Prostate Cancer to Develop Recommendations Regarding Inclusion of Intermediate-risk Disease, Biopsy Characteristics at Inclusion and Monitoring, and Surveillance Repeat Biopsy Strategy

Peter-Paul M. Willemse et al.

Summary: This qualitative systematic review explores the criteria for recruitment, monitoring, and reclassification in active surveillance protocols for localized prostate cancer. The study found that a minority of protocols included the use of MRI, and it recommends improvements in biopsy strategies for protocols without mandatory MRI use.

EUROPEAN UROLOGY (2022)

Add to Collection

Article Oncology

Metastasis and Mortality in Men With Low- and Intermediate-Risk Prostate Cancer on Active Surveillance

P. Travis Courtney et al.

Summary: Active surveillance may not be safe for patients with intermediate-risk prostate cancer, as it may increase the risk of metastasis and prostate cancer-specific mortality. However, carefully selected patients with favorable intermediate-risk prostate cancer may be suitable for active surveillance.

JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2022)

Add to Collection

Article Urology & Nephrology

Risk Stratification of Patients Candidate to Radical Prostatectomy Based on Clinical and Multiparametric Magnetic Resonance Imaging Parameters: Development and External Validation of Novel Risk Groups

Elio Mazzone et al.

Summary: This study developed and validated a novel classification integrating clinical and radiological parameters for predicting the risk of biochemical recurrence in prostate cancer patients. The classification showed higher accuracy compared to existing risk groups.

EUROPEAN UROLOGY (2022)

Add to Collection

Article Urology & Nephrology

An Algorithm to Personalize Nerve Sparing in Men with Unilateral High-Risk Prostate Cancer

Alberto Martini et al.

Summary: This study challenges current guidelines by proving that wide bilateral excision in men with unilateral high-risk prostate cancer is not justified. The study proposes performing nerve sparing and incremental nerve sparing in case of contralateral low and intermediate extraprostatic extension risk, respectively.

JOURNAL OF UROLOGY (2022)

Add to Collection

Review Urology & Nephrology

The current role of MRI for guiding active surveillance in prostate cancer

Guillaume Ploussard et al.

Summary: Active surveillance is a recommended treatment option for prostate cancer management, preserving oncological and functional outcomes. Additional monitoring using relevant parameters and MRI can improve initial stratification and reduce invasive procedures. However, abandoning biopsies without MRI progression is not yet recommended in routine practice.

NATURE REVIEWS UROLOGY (2022)

Add to Collection

Article Urology & Nephrology

Grade group 1 prostate cancer on biopsy: are we still missing aggressive disease in the era of image-directed therapy?

Michael Baboudjian et al.

Summary: This study retrospectively reviewed European RP data to assess the rate of adverse features at final pathology in patients with GGG1 at mpMRI-targeted biopsy. The results showed that 34.1% of patients with cT1-T2 cN0 GGG1-PCa had adverse features at final pathology, with only unfavorable intermediate-risk/high-risk disease predicting adverse features.

WORLD JOURNAL OF UROLOGY (2022)

Add to Collection

Review Urology & Nephrology

EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer-2020 Update. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent

Nicolas Mottet et al.

Summary: The 2020 EAU-EANM-ESTRO-ESUR-SIOG guidelines on screening, diagnosis, and treatment of localized prostate cancer summarize the most recent recommendations for clinical practice, including risk-adapted strategies, medical imaging utilization, biopsy techniques, patient classification, and treatment options. Recommendations include consideration of moderate hypofractionation for intermediate-risk patients and a combination of local treatment with long-term hormonal therapy for cN1 PCa patients.

EUROPEAN UROLOGY (2021)

Add to Collection

Article Oncology

Prostate Cancer, Version 1.2021 Featured Updates to the NCCN Guidelines

Edward Schaeffer et al.

Summary: The NCCN Guidelines for Prostate Cancer provide recommendations for staging and risk assessment post-diagnosis, with management options for localized, regional, and metastatic disease. The guidelines also cover disease monitoring and treatment of recurrent disease. The NCCN Prostate Cancer Panel meets annually to update recommendations based on new clinical data, aiming to provide the most effective care for patients.

JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2021)

Add to Collection

Article Oncology

Comparison of Multiparametric Magnetic Resonance Imaging-Targeted Biopsy With Systematic Transrectal Ultrasonography Biopsy for Biopsy-Naive Men at Risk for Prostate Cancer A Phase 3 Randomized Clinical Trial

Laurence Klotz et al.

Summary: In men at risk for prostate cancer, magnetic resonance imaging followed by selected targeted biopsy is noninferior to initial systematic biopsy in detecting grade group 2 or greater cancers.

JAMA ONCOLOGY (2021)

Add to Collection

Article Urology & Nephrology

Active Surveillance-Is It Feasible for Intermediate-risk Localised Prostate Cancer?

Subhabrata Mukherjee et al.

Summary: This study compared the outcome of active surveillance in low-risk and intermediate-risk prostate cancer patients, and found no significant difference in survival outcomes between the two groups. Carefully selected intermediate-risk patients could be offered the option of active surveillance.

EUROPEAN UROLOGY OPEN SCIENCE (2021)

Add to Collection

Review Urology & Nephrology

Active surveillance in intermediate-risk prostate cancer

Laurence Klotz

BJU INTERNATIONAL (2020)

Add to Collection

Article Urology & Nephrology

Active Surveillance of Grade Group 1 Prostate Cancer: Long-term Outcomes from a Large Prospective Cohort

Jeffrey J. Tosoian et al.

EUROPEAN UROLOGY (2020)

Add to Collection

Review Urology & Nephrology

Negative Predictive Value of Multiparametric Magnetic Resonance Imaging in the Detection of Clinically Significant Prostate Cancer in the Prostate Imaging Reporting and Data System Era: A Systematic Review and Meta-analysis

Niranjan J. Sathianathen et al.

EUROPEAN UROLOGY (2020)

Add to Collection

Review Urology & Nephrology

EAU-EANM-ESTRO-ESUR-SIOG Prostate Cancer Guideline Panel Consensus Statements for Deferred Treatment with Curative Intent for Localised Prostate Cancer from an International Collaborative Study (DETECTIVE Study)

Thomas B. L. Lam et al.

EUROPEAN UROLOGY (2019)

Add to Collection

Article Medicine, General & Internal

MRI-Targeted or Standard Biopsy for Prostate-Cancer Diagnosis

V Kasivisvanathan et al.

NEW ENGLAND JOURNAL OF MEDICINE (2018)

Add to Collection

Article Urology & Nephrology

Intermediate-Term Outcomes for Men with Very Low/Low and Intermediate/High Risk Prostate Cancer Managed by Active Surveillance

Yaw A. Nyame et al.

JOURNAL OF UROLOGY (2017)

Add to Collection

Article Urology & Nephrology

PI-RADS Prostate Imaging - Reporting and Data System: 2015, Version 2

Jeffrey C. Weinreb et al.

EUROPEAN UROLOGY (2016)

Add to Collection

Article Oncology

Active Surveillance for the Management of Localized Prostate Cancer (Cancer Care Ontario Guideline): American Society of Clinical Oncology Clinical Practice Guideline Endorsement

Ronald C. Chen et al.

JOURNAL OF CLINICAL ONCOLOGY (2016)

Add to Collection

Article Urology & Nephrology

Active surveillance for the management of localized prostate cancer: Guideline recommendations

Chris Morash et al.

CUAJ-CANADIAN UROLOGICAL ASSOCIATION JOURNAL (2015)

Add to Collection

Review Urology & Nephrology

Observational studies and the natural history of screen-detected prostate cancer

Peter C. Albertsen

CURRENT OPINION IN UROLOGY (2015)

Add to Collection

Article Urology & Nephrology

Contemporary Use of Initial Active Surveillance Among Men in Michigan with Low-risk Prostate Cancer

Paul R. Womble et al.

EUROPEAN UROLOGY (2015)

Add to Collection

Article Oncology

Intermediate and Longer-Term Outcomes From a Prospective Active-Surveillance Program for Favorable-Risk Prostate Cancer

Jeffrey J. Tosoian et al.

JOURNAL OF CLINICAL ONCOLOGY (2015)

Add to Collection

Review Urology & Nephrology

Active surveillance: patient selection

Laurence Klotz

CURRENT OPINION IN UROLOGY (2013)

Add to Collection

Article Radiology, Nuclear Medicine & Medical Imaging

ESUR prostate MR guidelines 2012

Jelle O. Barentsz et al.

EUROPEAN RADIOLOGY (2012)

Add to Collection

Article Urology & Nephrology

Patient acceptance of active surveillance as a treatment option for low-risk prostate cancer

B. Joyce Davison et al.

BJU INTERNATIONAL (2011)

Add to Collection

Article Business

Segmentation approaches in data-mining: A comparison of RFM, CHAID, and logistic regression

John A. McCarty et al.

JOURNAL OF BUSINESS RESEARCH (2007)

Add to Collection

Article Medicine, General & Internal

20-year outcomes following conservative management of clinically localized prostate cancer

PC Albertsen et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2005)

Add to Collection

© Peeref 2019-2024. All rights reserved.